Delivery Order SPE2DB22D3009-SPE2DB24FBA70

Award Date 7/16/24
Potential Completion Date 7/17/24
Potential Value $1.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,563,312,292 units of Clindamycin Phosphate 1% Foam, 50 grams. The total potential value of the order is $3,521.02, with a completion date of January 12, 2024. Amerisourcebergen Drug Corp has previously received numerous federal contract awards from DLA to supply pharmaceuticals, medical supplies, and related...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Clindamycin Phosphate 1% Foam, 100 grams, with a ceiling value of $1,217.44 and a performance period through June 10, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00,...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $13,835.36, is for the delivery of Clindamycin Phosphate 1% Foam in 100 gram quantities. The contract is a firm fixed-price delivery order, with an ultimate completion date of July 9, 2025. This contract award is not designated as a set-aside, indicating open competition....
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of 4565366325 - Clindamycin Phosphate 1% Foam, 50 gm. The order has a firm fixed-price of $2,838.07 and the period of performance runs through August 7, 2024. As a major pharmaceutical distributor, AmerisourceBergen provides a wide range of prescription medications, over-the-counter drugs, and medical supplies to support various government agencies and healthcare programs,...
This federal contract award, valued at $2,969.13, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4567090332 - Clindamycin Phosphate 1% Foam 100GM, a pharmaceutical product, with a completion date of January 30, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running...
This federal contract award is a delivery order worth $3,392.60 issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Clindamycin Phosphate 1% Foam, a pharmaceutical product, with a completion date of May 15, 2025. The contract is a Firm Fixed Price (FFP) arrangement and is not set aside for any particular business type. Amerisourcebergen Drug Corp holds a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,310.66 Delivery Order contract is for the supply of Clindamycin Phosphate 1% Foam, a pharmaceutical product, with a completion date of November 7, 2024. The contract has a Firm Fixed Price pricing type and is not designated with any set-aside requirements, indicating open competition. Amerisourcebergen holds a...
This federal contract award is for the delivery of Clindamycin Phosphate 1% Foam, a pharmaceutical product, to the Defense Logistics Agency (DLA). The fixed-price delivery order, valued at $1,458.95, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on May 14, 2025, with a performance period extending to May 15, 2025. The contract is not designated as a set-aside and was awarded under the DLA's broader $999,999,999.00 Indefinite Delivery Contract (IDC) with...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Clindamycin Phosphate 1% Foam, 50 grams. The contract has a firm fixed price of $1,388.58 and a completion date of June 25, 2025. The contract is not set aside and was awarded on June 24, 2025. Amerisourcebergen Drug Corp is a for-profit organization that serves as a critical supplier of medical and pharmaceutical products...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $1,750.74 firm fixed-price delivery order covers the provision of Clindamycin Phosphate 1% Foam in 50 gram containers. The contract has an ultimate completion date of June 15, 2023 and was awarded on June 14, 2023. It does not have a set-aside designation, indicating the contract was competed openly. Amerisourcebergen Drug Corp holds...
  • SPE2DB22D3009
    Indefinite Delivery Contract
  • SPE2DB22D3009-SPE2DB24FBA70
    Delivery Order

This is a $1,354.58 firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation for the supply of 4,565,166,349 units of Clindamycin Phosphate 1% Foam, a prescription pharmaceutical product. The order has a completion date of July 17, 2024. AmerisourceBergen, a major pharmaceutical distributor, has been awarded multiple federal contracts and indefinite delivery vehicles (IDVs) by the DLA and other agencies to provide a wide range of medical commodities, including specialty medications, generic drugs, and medical supplies, to support military treatment facilities, veterans' healthcare, and other government healthcare programs. This particular award is not designated as a set-aside contract.

Generated 10/15/24, 9:43 PM